Relay Therapeutics Jumps on Data Update

Published by
The Street

By Maxx Chatsko An early look at an ongoing study hints at the value of the company’s unique approach. An emerging crop of drug developers is using artificial intelligence, machine learning, and sometimes supercomputers to design safer and more effective drugs. Data from human patients remains scarce, non-existent, or hardly unique compared to more traditional drug development approaches. There’s a healthy dose of skepticism among analysts and industry titans. The latest update from Relay Therapeutics (RLAY) – Get Relay Therapeutics Inc. Report provides early validation for a technology-enable…

Read More

See also  Siam Square hosts new green building

Leave a Reply